Literature DB >> 11879863

Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state.

Robert A S Ariëns1, Marlies de Lange, Harold Snieder, May Boothby, Tim D Spector, Peter J Grant.   

Abstract

BACKGROUND: Activation markers of coagulation and fibrinolysis are increased in individuals at risk of coronary-artery disease and other thrombotic disorders--a condition defined as the prethrombotic state. We aimed to find out the extent to which the prethrombotic state is determined by genetic factors.
METHODS: We analysed concentrations of prothrombin, prothrombin fragment 1+2, thrombin-antithrombin complex, crosslinked fibrin degradation product D-dimer, and thrombin-activatable fibrinolysis inhibitor by ELISA in 118 monozygotic and 112 dizygotic unselected female twins aged 21-73 years from the St Thomas' UK Adult Twin Registry. We used quantitative genetic-model fitting to estimate heritability.
FINDINGS: We found significant heritabilities in concentrations of the activation markers in plasma. Genetic factors contributed 45, 40, and 65% of the variation in concentrations of fragment 1+2, thrombin-antithrombin complex, and D-dimer, respectively. Age was important only in fragment 1+2 concentrations, in which it accounted for 12% of the variation. The remaining variation could be attributed to unique environmental factors. Variation in concentrations of precursor prothrombin in plasma was determined by 57% heritability, and that of zymogen thrombin-activatable fibrinolysis inhibitor showed a very strong genetic component (82%).
INTERPRETATION: The activation mechanisms of the coagulation and fibrinolytic systems, and therefore the prethrombotic state, are controlled to a substantial degree by genetic factors. Genes influencing activation of haemostasis are likely to be an important component of the overall thrombotic tendency in the general population.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11879863     DOI: 10.1016/S0140-6736(02)07813-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  23 in total

1.  Mutations R67X and W303X of the protein Z-dependent protease inhibitor gene and venous thromboembolic disease: a case-control study in Italian subjects.

Authors:  Dora Fabbro; Giovanni Barillari; Giuseppe Damante
Journal:  J Thromb Thrombolysis       Date:  2007-02       Impact factor: 2.300

2.  Genetic polymorphisms associated with carotid artery intima-media thickness and coronary artery calcification in women of the Kronos Early Estrogen Prevention Study.

Authors:  Virginia M Miller; Tanya M Petterson; Elysia N Jeavons; Abhinita S Lnu; David N Rider; John A Heit; Julie M Cunningham; Gordon S Huggins; Howard N Hodis; Matthew J Budoff; Nanette Santoro; Paul N Hopkins; Rogerio A Lobo; JoAnn E Manson; Frederick Naftolin; Hugh S Taylor; S Mitchell Harman; Mariza de Andrade
Journal:  Physiol Genomics       Date:  2012-11-27       Impact factor: 3.107

3.  A genetic association study of D-dimer levels with 50K SNPs from a candidate gene chip in four ethnic groups.

Authors:  Lu-Chen Weng; Weihong Tang; Stephen S Rich; Nicholas L Smith; Susan Redline; Christopher J O'Donnell; Saonli Basu; Alexander P Reiner; Joseph A Delaney; Russell P Tracy; Cameron D Palmer; Taylor Young; Qiong Yang; Aaron R Folsom; Mary Cushman
Journal:  Thromb Res       Date:  2014-05-20       Impact factor: 3.944

Review 4.  Epidemiology of venous thromboembolism.

Authors:  John A Heit
Journal:  Nat Rev Cardiol       Date:  2015-06-16       Impact factor: 32.419

5.  Genetic admixture is associated with plasma hemostatic factor levels in self-identified African Americans and Hispanics: the Multi-Ethnic Study of Atherosclerosis.

Authors:  P L Lutsey; C L Wassel; M Cushman; M M Sale; J Divers; A R Folsom
Journal:  J Thromb Haemost       Date:  2012-04       Impact factor: 5.824

6.  Genetic variation within the anticoagulant, procoagulant, fibrinolytic and innate immunity pathways as risk factors for venous thromboembolism.

Authors:  J A Heit; J M Cunningham; T M Petterson; S M Armasu; D N Rider; M DE Andrade
Journal:  J Thromb Haemost       Date:  2011-06       Impact factor: 5.824

7.  A genome-wide exploration suggests an oligogenic model of inheritance for the TAFI activity and its antigen levels.

Authors:  Maria Sabater-Lleal; Alfonso Buil; Juan Carlos Souto; Laura Alamsy; Montserrat Borrell; Mark Lathrop; John Blangero; Jordi Fontcuberta; José Manuel Soria
Journal:  Hum Genet       Date:  2008-06-18       Impact factor: 4.132

Review 8.  The epidemiology of venous thromboembolism in the community: implications for prevention and management.

Authors:  John A Heit
Journal:  J Thromb Thrombolysis       Date:  2006-02       Impact factor: 2.300

9.  Identification of quantitative trait loci for fibrin clot phenotypes: the EuroCLOT study.

Authors:  Frances M K Williams; Angela M Carter; Bernet Kato; Mario Falchi; Lise Bathum; Gabriela Surdulescu; Kirsten Ohm Kyvik; Aarno Palotie; Tim D Spector; Peter J Grant
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-01-15       Impact factor: 8.311

10.  Association of D-dimer levels with all-cause mortality in a healthy adult population: findings from the MOLI-SANI study.

Authors:  Augusto Di Castelnuovo; Amalia de Curtis; Simona Costanzo; Mariarosaria Persichillo; Marco Olivieri; Francesco Zito; Maria Benedetta Donati; Giovanni de Gaetano; Licia Iacoviello
Journal:  Haematologica       Date:  2013-05-03       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.